Key result
Tafamidis stabilizes cardiac structure and function, preserving LVEF in ~85% of ATTR-CM patients at 12 months.
Why the study?
The effects of tafamidis treatment on echocardiographic measures of cardiac structure and function in Chinese patients with transthyretin amyloid cardiomyopathy were not fully characterized.
Does tafamidis stabilize echocardiographic measures of heart structure and function in Chinese patients with transthyretin amyloid cardiomyopathy?
Cohort (n=53)
Open-label
Yes
Does tafamidis stabilize echocardiographic measures of heart structure and function in Chinese patients with transthyretin amyloid cardiomyopathy?
Tafamidis treatment halts the progression of structural and functional echocardiographic deterioration in Chinese patients with ATTR-CM over 12 months.
Answers are grounded in this paper and cite their sources.
Tafamidis was associated with echocardiographic stabilization in Chinese ATTR-CM; hypothesis-generating and requires randomized confirmation.
Background A multicenter, open-label, post-approval commitment study previously demonstrated the safety and efficacy of tafamidis in Chinese patients with transthyretin amyloid cardiomyopathy (ATTR-CM). This post hoc analysis evaluated patients’ structural and functional echocardiographic changes during treatment. Methods Data were analyzed from 53 Chinese patients with ATTR-CM and an end-diastolic interventricular septal (IVS) wall thickness > 12 mm. Results At baseline, patients’ mean (standard deviation [SD]) age was 60 (12) years, 89% were male, and 94% had variant ATTR-CM. The majority (81%) had New York Heart Association class II symptoms (class I: 6%; class III: 13%). Patients’ mean (SD) baseline left ventricular (LV) ejection fraction was 53% (10.9), stroke volume was 46 (17.9) mL, LV global longitudinal strain (GLS) was −14% (3.0), IVS wall thickness was 17 (3.5) mm, and posterior wall thickness (PWT) was 15 (3.4) mm. Patients received open-label tafamidis free acid 61 mg for 12 months with echocardiographic assessments at baseline, month 6, and month 12. After 6 and 12 months of treatment there were no clinically relevant mean changes from baseline in cardiac structure or function measures. Overall, 85% of patients had < 5% decrease in LV ejection fraction, 83% had < 5 mL decrease in stroke volume, 83% had < 1% increase in GLS, 80% had < 2-mm increase in IVS wall thickness, and 85% had < 2-mm increase in PWT from baseline to month 12. Conclusion Stability in echocardiographic measures of cardiac structure and function was observed over 12 months of tafamidis treatment in Chinese patients, predominantly with variant ATTR-CM. ClinicalTrials.gov, NCT04814186, Registered 10 March 2021, https://clinicaltrials.gov/study/NCT04814186
No takes yet. Share an insight, caveat, or question.
Tian et al. (2026) conducted a cohort in Transthyretin amyloid cardiomyopathy (ATTR-CM) (n=53). Tafamidis was evaluated on Patients with < 5% decrease in left ventricular ejection fraction from baseline to month 12. Tafamidis stabilized echocardiographic measures of cardiac structure and function over 12 months in Chinese patients with ATTR-CM, with 85% of patients demonstrating a <5% decrease in left ventricular ejection fraction.
Synapse has enriched 10 related papers. Consider them for comparative context: